Formalin-fixed biological specimens are an invaluable resource for the extraction of DNA, RNA and protein. By providing information on single-gene mutations through next-generation sequencing (NGS) processes, FFPE (Formalin-Fixed Paraffin-Embedded) samples enable precision medicine and cancer genetics studies. In addition, FFPE tissues are more readily available and easier to handle in clinical practice than fresh frozen tissues. However, the physical and chemical modifications following formalin fixation can pose difficulties — such as DNA degradation, cross-linking and fragmentation — for NGS processes.
In this webinar, the featured speaker shares insights into FFPE fixation conditions, quality metrics that are most predictive of success, and how to leverage assay design when working with these precious specimens. Highlights of the Personalis clinical laboratory experience in providing robust genomic solutions for clinical research and diagnostic applications from both limited and challenging studies will be presented.
Register for this webinar to gain insights into maximizing immuno-oncology insights for challenging clinical samples with NGS solutions.
Erin N. Newburn, MS, PhD, Director, Field Applications Scientist, Personalis, Inc.
Dr. Erin Newburn joined Personalis as a Field Applications Scientist in 2013 with over 13 years of research experience in the areas of molecular biology, genetics and biotechnology. As the Director, Field Applications Scientist, Erin’s team has the responsibility of providing both pre- and post-sale technical support for the Personalis NeXT Platform including both the ImmunoID NeXT and NeXT Personal solutions.
Erin completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her PhD from the Ohio State University in integrated biomedical science as a Presidential Fellow.Message Presenter
Who Should Attend?
Professionals from biopharmaceutical organizations with cancer drug pipelines working within:
- Immuno-Oncology Clinical Development Programs
- Clinical Program Managers or Project Managers
- Biomarker and CDx Laboratory Directors and Scientists
- Chief Medical and Scientific Officers
- Bioinformatics and Genomics
- Medical Affairs
Who want to better understand how to leverage comprehensive immunogenomic sequencing of clinical trial samples, using both tissue and liquid biopsy, to help drive biomarker discovery and drug development programs.
What You Will Learn
Attendees will gain insights into:
- Formalin fixation conditions and quality metrics
- Leveraging assay design when working with formalin-fixed paraffin-embedded samples
Personalis, Inc. is leading the oncology field in developing patient-centered diagnostics by delivering tumor-informed comprehensive insights. The Personalis NeXT Platform® and suite of products are designed to capture the complex and evolving understanding of cancer, providing biopharmaceutical partners and clinicians with information on 20,000 human genes and the immune system from a single tissue sample.
With NeXT PersonalTM these insights are expanded into a tumor-informed, ultra-sensitive ctDNA analysis, enabling earlier detection of disease recurrence (MRD) in a broader range of indications at earlier stages. Personalis operates a CAP/CLIA-accredited laboratory in the United States, delivering our NeXT DxTM test, a comprehensive genomic testing solution that enables physicians to identify potential targeted and/or immunotherapy options, evidence of drug resistance and clinical trial options for patients with solid tumors. Personalis also operates a Wholly Foreign-Owned Enterprise and laboratory in China, with HGRAC approval of NeXT Platform to provide retrospective testing in clinical trials.